Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Impact of SARS-CoV-2 Vaccines on Covid-19 Incidence and Mortality in the United States

Fang Fang, John David Clemens, Zuo-Feng Zhang, Timothy F. Brewer
doi: https://doi.org/10.1101/2021.11.16.21266360
Fang Fang
1Department of Epidemiology, Fielding School of Public Health, University of California at Los Angeles (UCLA), Los Angeles, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John David Clemens
1Department of Epidemiology, Fielding School of Public Health, University of California at Los Angeles (UCLA), Los Angeles, CA, USA
2International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh
3International Vaccination Institute (IVI), Seoul, the Republic of Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zuo-Feng Zhang
1Department of Epidemiology, Fielding School of Public Health, University of California at Los Angeles (UCLA), Los Angeles, CA, USA
4Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA, USA
5Center for Human Nutrition, Department of Medicine, UCLA David Geffen School of Medicine, University of California at Los Angeles (UCLA), Los Angeles, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: TBrewer@mednet.ucla.edu zfzhang@ucla.edu
Timothy F. Brewer
1Department of Epidemiology, Fielding School of Public Health, University of California at Los Angeles (UCLA), Los Angeles, CA, USA
6Division of Infectious Diseases, UCLA David Geffen School of Medicine, Los Angeles, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: TBrewer@mednet.ucla.edu zfzhang@ucla.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background Despite safe and effective vaccines to prevent Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) infections and disease, a substantial minority of the US remains resistant to getting vaccinated. It is imperative to know if expanding vaccination rates could reduce community-wide Coronavirus 2019 (COVID-19) disease, not just among those vaccinated.

Methods Negative binomial models were used to estimate associations between U.S. county-level vaccination rates and county-wide COVID-19 incidence and mortality between April 23rd and September 30th, 2021. A two-week lag and a four-week lag were introduced to assess vaccination rate impact on incidence and mortality, respectively. Stratified analyses were performed for county vaccination rates 40%, and before and after Delta became the dominant variant.

Findings Among 3,070 counties, each percentage increase in population vaccination rates reduced county-wide COVID-19 incidence by 0·9% (relative risk (RR) 0. 9910 (95% CI: 0·9869, 0·9952)) and mortality by 1·9% (RR 0·9807 (95% CI: 0·9745, 0·9823)). Among counties with vaccination coverage >40%, each percentage increase in vaccination rates reduced COVID-19 disease by 1·5%, RR 0·9850 (95% CI: 0·9793, 0·9952) and mortality by 2·7% (RR 0·9727 (95% CI: 0·9632, 0·9823)). These associations were not observed among counties with <40% vaccination rates. Increasing vaccination rates from 40% to 80% would have reduced COVID-19 cases by 45·4% (RR 0·5458 (95% CI: 0·4335, 0·6873)) and deaths by 67·0% (RR 0·3305 (95% CI: 0·2230, 0·4898)). An estimated 5,989,952 COVID-19 cases could have been prevented and 127,596 lives saved had US population vaccination rates increased from 40% to 80%.

Interpretations Increasing U.S. SARS-CoV-2 vaccination rates results in population-wide reductions in COVID-19 incidence and mortality. Furthermore, increasing vaccination rates above 40% has protective effects among non-vaccinated persons. Given ongoing vaccine hesitancy in the U.S., increasing vaccination rates could better protect the entire community and potentially reach herd immunity.

Funding National Cancer Institute

Competing Interest Statement

F Fang and TF Brewer held stock in Pfizer. All other authors declare no competing interests.

Funding Statement

NIH/NCI T32 CA009142

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Johns Hopkins University Center for Systems Science and Engineering Coronavirus Resource Center (CSSE, https://github.com/CSSEGISandData/COVID-19/blob/master/csse_covid_19_data/csse_covid_19_time_series/time_series_covid19_confirmed_US.csv) Covid Act Now (https://apidocs.covidactnow.org/data-definitions/#vaccinations) GitHub repository (https://github.com/wxwx1993/PM_COVID) The US Census/American Community Survey The County Health Rankings & Roadmaps program (https://www.countyhealthrankings.org/explore-health-rankings/rankings-data-documentation) ArcGIS hub (https://hub.arcgis.com/datasets/geoplatform::hospitals/about) Economic Research Service (https://www.ers.usda.gov/data-products/rural-urban-continuum-codes/) Boston University of Public Health (https://docs.google.com/spreadsheets/d/1zu9qEWI8PsOI_i8nI_S29HDGHlIp2lfVMsGxpQ5tvAQ/edit#gid=97365544)

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present work are contained in the manuscript

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted November 17, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Impact of SARS-CoV-2 Vaccines on Covid-19 Incidence and Mortality in the United States
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Impact of SARS-CoV-2 Vaccines on Covid-19 Incidence and Mortality in the United States
Fang Fang, John David Clemens, Zuo-Feng Zhang, Timothy F. Brewer
medRxiv 2021.11.16.21266360; doi: https://doi.org/10.1101/2021.11.16.21266360
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Impact of SARS-CoV-2 Vaccines on Covid-19 Incidence and Mortality in the United States
Fang Fang, John David Clemens, Zuo-Feng Zhang, Timothy F. Brewer
medRxiv 2021.11.16.21266360; doi: https://doi.org/10.1101/2021.11.16.21266360

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (214)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1091)
  • Dentistry and Oral Medicine (194)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (497)
  • Epidemiology (9747)
  • Forensic Medicine (5)
  • Gastroenterology (480)
  • Genetic and Genomic Medicine (2299)
  • Geriatric Medicine (221)
  • Health Economics (461)
  • Health Informatics (1548)
  • Health Policy (729)
  • Health Systems and Quality Improvement (600)
  • Hematology (236)
  • HIV/AIDS (500)
  • Infectious Diseases (except HIV/AIDS) (11623)
  • Intensive Care and Critical Care Medicine (615)
  • Medical Education (236)
  • Medical Ethics (67)
  • Nephrology (256)
  • Neurology (2137)
  • Nursing (133)
  • Nutrition (332)
  • Obstetrics and Gynecology (424)
  • Occupational and Environmental Health (516)
  • Oncology (1171)
  • Ophthalmology (363)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (145)
  • Palliative Medicine (50)
  • Pathology (308)
  • Pediatrics (693)
  • Pharmacology and Therapeutics (298)
  • Primary Care Research (265)
  • Psychiatry and Clinical Psychology (2168)
  • Public and Global Health (4640)
  • Radiology and Imaging (775)
  • Rehabilitation Medicine and Physical Therapy (451)
  • Respiratory Medicine (622)
  • Rheumatology (273)
  • Sexual and Reproductive Health (224)
  • Sports Medicine (208)
  • Surgery (250)
  • Toxicology (42)
  • Transplantation (120)
  • Urology (94)